PerkinElmer and Predictive Diagnostics announce Discovery of Blood Biomarkers for Alzheimer's Disease

22-Apr-2005

PerkinElmer Inc. and Predictive Diagnostics, Inc., a wholly owned subsidiary of Large Scale Biology Corporation, announced that they have found a series of biomarkers that appear to differ in persons with Alzheimer's disease compared to persons without cognitive impairment, using a simple blood test.

The collaborative study, initiated by PerkinElmer and David Bennett, M.D., Director of the Rush Alzheimer's Disease Center, Rush University Medical Center (Chicago, Illinois), is among the first study of its kind to describe a potential diagnostic blood test for Alzheimer's disease, although the results will need replication in a separate study.

The blood analysis was carried out using PerkinElmer's BioXPRESSION(tm) Biomarker platform and Predictive Diagnostic's proprietary BAMF(tm) technology to identify patterns of proteins and peptides that distinguish Alzheimer's disease patients from those without clinical signs. The serum samples used in the study were donated by the Rush Alzheimer's Disease Center.

In numerous collaborative studies, Predictive Diagnostics has demonstrated the capability of its BAMF(tm) technology to accurately diagnose cancers such as breast, lung, pancreatic and prostate, as well as multiple sclerosis. Predictive Diagnostics believes its diagnostic tests will provide better patient outcome through early detection of cancer and other serious diseases and significantly reduce the cost of healthcare associated with treatment of such diseases.

https://www.bionity.com/en/news/45365/perkinelmer-and-predictive-diagnostics-announce-discovery-of-blood-biomarkers-for-alzheimer-s-disease.html